ATM and cancer: Single-agent activity has been observed in ATM-deficient tumors, including lymphomas; in a first-in-human study, 30% of evaluable patients achieved ≥4-month stable disease and two patients with ATM-loss cancers achieved partial responses (NCT03188965) [109].